Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1979 1
1982 1
1983 1
1984 3
1988 2
1991 1
1993 3
1994 2
1995 2
1996 4
1997 3
1998 5
1999 4
2000 2
2001 8
2002 7
2003 2
2004 5
2005 9
2006 6
2007 5
2008 7
2009 5
2010 8
2011 11
2012 21
2013 15
2014 21
2015 27
2016 33
2017 28
2018 30
2019 31
2020 26
2021 24
2022 28
2023 29
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Results by year

Filters applied: . Clear all
Page 1
FcRn Inhibitor Therapies in Neurologic Diseases.
Alfaidi N, Karmastaji S, Matic A, Bril V. Alfaidi N, et al. Among authors: bril v. CNS Drugs. 2024 May 9. doi: 10.1007/s40263-024-01090-3. Online ahead of print. CNS Drugs. 2024. PMID: 38724842 Review.
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, De Bleecker JL, Murai H, Meisel A, Beydoun SR, Pasnoor M, Guglietta A, Van Hoorick B, Steeland S, T'joen C, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT+ Study Group. Howard JF Jr, et al. Among authors: bril v. Front Neurol. 2024 Jan 17;14:1284444. doi: 10.3389/fneur.2023.1284444. eCollection 2023. Front Neurol. 2024. PMID: 38318236 Free PMC article.
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study.
Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, Quan D, Sevilla T, Jouvin MH, Jin J, Karcher K, Ramchandren S, Sun H, Ling L, Zhu Y, Arroyo S; Vivacity-MG Phase 2 Study Group. Antozzi C, et al. Among authors: bril v. Neurology. 2024 Jan 23;102(2):e207937. doi: 10.1212/WNL.0000000000207937. Epub 2023 Dec 21. Neurology. 2024. PMID: 38165333 Free PMC article. Clinical Trial.
Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extension.
Nowak RJ, Breiner A, Bril V, Allen JA, Khan S, Levine T, Jacobs DH, Sahagian G, Siddiqi ZA, Xu J, Macias WL, Benatar M; ASCEND MG Study Group. Nowak RJ, et al. Among authors: bril v. Ann Clin Transl Neurol. 2024 Jan;11(1):194-206. doi: 10.1002/acn3.51946. Epub 2023 Dec 7. Ann Clin Transl Neurol. 2024. PMID: 38062618 Free PMC article. Clinical Trial.
Fasted C-Peptide Distribution and Associated Clinical Factors in Adults With Longstanding Type 1 Diabetes: Analysis of the Canadian Study of Longevity in Type 1 Diabetes.
Lanctôt SO, Lovblom LE, Lewis EJH, Morris M, Cardinez N, Scarr D, Bakhsh A, Abuabat MI, Lovshin JA, Lytvyn Y, Boulet G, Bussières A, Brent MH, Paul N, Bril V, Cherney DZI, Perkins BA. Lanctôt SO, et al. Among authors: bril v. Can J Diabetes. 2024 Mar;48(2):89-96. doi: 10.1016/j.jcjd.2023.11.001. Epub 2023 Nov 7. Can J Diabetes. 2024. PMID: 37944665
378 results